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Background: Several cardiac biomarkers have established their prognostic value in patients at risk for major adverse cardiac events, although 
their relative prognostic significance, individually or combined, has not been prospectively validated
Methods: We measured plasma levels of B-type natriuretic peptide (BNP), myeloperoxidase (MPO), and high-sensitivity C-reactive protein (hsCRP) 
in 3,635 consecutive stable patients undergoing elective cardiac catheterization without acute coronary syndrome (cardiac troponin negative), and 
examined their relationship with incident major adverse cardiac events (MACE = death, non-fatal myocardial infarction [MI], stroke) over 3 years.
Results: In our study cohort (mean age 63±11 years, 65% male, 33% history of MI, 29% diabetes mellitus), median [interquartile range] levels of 
hsCRP, BNP, and MPO were 2.00[0.91-4.47] pg/mL, 83[34-200] pg/mL, and 103[70-195] pmol/L, respectively. A cardiac biomarker score based on 
the sum total of “positive” biomarkers using established cutoffs for BNP, CRP and MPO provided strong and independent prediction of future risk of 
incident MACE at 3 years (HR: 7.61 [95%CI: 4.98-11.65]), even after adjusted for traditional risk factors (6.11[95%CI: 3.98-9.38]).
Conclusions: In stable patients undergoing elective cardiac evaluation, an assessment of cardiac biomarker score integrating systemic biomarkers 
of myocardial dysfunction (BNP), plaque vulnerability (MPO), and systemic inflammation (hsCRP) provide independent prognostic value for long-term 
adverse clinical events.
